Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study

This multicenter, prospective trial was conducted to develop an effective and safe reinduction regimen for marrow-relapsed pediatric acute lymphoblastic leukemia (ALL) by modifying the dose of idarubicin. Between 2006 and 2009, the trial accrued 44 patients, 1 to 21 years old with first marrow-relap...

Descripción completa

Detalles Bibliográficos
Autores principales: Koh, Kyung-Nam, Im, Ho Joon, Kim, Hyery, Kang, Hyoung Jin, Park, Kyung Duk, Shin, Hee Young, Ahn, Hyo Seop, Lee, Ji Won, Yoo, Keon Hee, Sung, Ki Woong, Koo, Hong Hoe, Lim, Young Tak, Park, Jun Eun, Park, Byung-Kiu, Park, Hyeon Jin, Seo, Jong Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334163/
https://www.ncbi.nlm.nih.gov/pubmed/28244291
http://dx.doi.org/10.3346/jkms.2017.32.4.642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334163/
https://www.ncbi.nlm.nih.gov/pubmed/28244291
http://dx.doi.org/10.3346/jkms.2017.32.4.642

Ejemplares similares